Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine (SHIM)

12 september 2026 uppdaterad av: Ukrainian Institute on Public Health Policy

The goal of this pragmatic, quasi-experimental cluster trial is to evaluate whether simplified, onsite hepatitis C virus (HCV) treatment integrated into opioid agonist maintenance therapy (OAMT) clinics improves cure rates compared with referral-based care in Ukraine . The study includes adults (18 years and older) receiving OAMT with confirmed chronic HCV infection and no prior HCV treatment.

The main questions it aims to answer are:

  • Does onsite Simplified HCV Integrated Management (SHIM) increase the proportion of patients achieving sustained virologic response 12 weeks after treatment completion (SVR12) compared with case management and referral (CMR) to specialist clinics?
  • Does adding provider pay-for-performance (P4P) incentives to SHIM further improve progression along the HCV treatment cascade and SVR12 rates?

Researchers compared three models of care across 13 OAMT clinics in 12 Ukrainian cities:

  • Case Management and Referral (CMR): structured referral to off-site specialist clinics for HCV treatment
  • SHIM: simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
  • SHIM + P4P: SHIM with provider incentives linked to completion of key cascade milestones All SHIM clinics were supported by Project ECHO telementoring to strengthen clinician capacity . The study used nationally procured direct-acting antivirals (DAAs) under routine program conditions and did not reimburse diagnostic costs.

Between February 2023 and December 2024, 616 eligible patients were enrolled .

Participants:

  • Completed confirmatory HCV RNA testing
  • Underwent simplified pretreatment clinical and laboratory assessment
  • Received 12 weeks of pan-genotypic DAA treatment either onsite (SHIM arms) or at specialist clinics (CMR arm)
  • Attended follow-up visits during treatment for adherence assessment and counseling
  • Were prescribed HCV RNA testing 12 weeks after treatment completion to confirm cure (SVR12) The primary outcome was SVR12. Secondary outcomes included completion of pretreatment evaluation, treatment initiation, treatment completion, and completion of SVR assessment.

This study evaluates HCV care under real-world conditions during ongoing national treatment scale-up in Ukraine. The findings inform whether integrating simplified HCV treatment into OAMT clinics-and aligning provider incentives-can improve cure rates and accelerate progress toward HCV elimination in high-burden populations.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

616

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Kyiv, Ukraina, 01054
        • Ukrainian Institute on Public Health Policy

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • currently receiving treatment at the selected OAT site (implying a diagnosis of opioid dependence according to ICD 10);
  • aged 18 years or older;
  • residing within the study catchment area; and
  • having a positive HCV antibody test documented in the medical chart

Exclusion Criteria:

  • previous HCV treatment history;
  • active tuberculosis (assessed using 4-item screening questionnaire and confirmed according to the current national protocol);
  • pregnant or planning pregnancy in the next 6 months;
  • planning to move to another city in the next 6 months;
  • unwillingness to undergo confirmatory HCV RNA PCR test at their own expense and treat HCV

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Hälsovårdsforskning
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Case Management and Referral
structured referral to off-site specialist clinics for HCV treatment
structured referral to off-site specialist clinics for HCV treatment
Experimentell: Simplified HCV Integrated Management
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
Experimentell: Simplified HCV Integrated Management + Pay-for-performance
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians with provider incentives linked to completion of key cascade milestones
simplified onsite HCV testing, evaluation, treatment, and follow-up delivered by OAMT physicians
provider incentives linked to completion of key cascade milestones

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sustained virologic response
Tidsram: Up to 24 weeks after treatment completion
Number of participants who have HCV RNA below the limit of quantitation (≤50 IU/mL) based on clinical records
Up to 24 weeks after treatment completion

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Completion of all pretreatment diagnostic assessments
Tidsram: Through study completion, an average of 2 weeks after baseline
Number of participants who complete all pretreatment diagnostic assessments according to the SHIM algorithm (complete blood count, basic metabolic panel (including creatinine), hepatic function panel, fibrosis assessment, and HBsAg testing) based on clinical records
Through study completion, an average of 2 weeks after baseline
Treatment initiation
Tidsram: Through study completion, an average of 4 weeks after baseline
Number of participants who are prescribed treatment for HCV infection based on clinical records
Through study completion, an average of 4 weeks after baseline
Treatment completion
Tidsram: Through study completion, an average of 14 weeks after baseline
Number of participants who complete the full course of HCV treatment as prescribed based on clinical records
Through study completion, an average of 14 weeks after baseline
SVR assessment completion
Tidsram: Up to 24 weeks after treatment completion
Number of participants who complete HCV RNA testing for SVR confirmation based on clinical records
Up to 24 weeks after treatment completion
HCV reinfection
Tidsram: 12 months after treatment completion
Number of participants who receive a positive result of HCV RNA test at 12 months after treatment completion, based on clinical records
12 months after treatment completion

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

4 mars 2023

Primärt slutförande (Faktisk)

31 oktober 2025

Avslutad studie (Faktisk)

31 december 2025

Studieregistreringsdatum

Först inskickad

27 februari 2026

Först inskickad som uppfyllde QC-kriterierna

28 april 2026

Första postat (Faktisk)

6 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

Tidsram för IPD-delning

January 1, 2026 - June 30, 2029

Kriterier för IPD Sharing Access

Reasonable request to the principal investigator

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera